Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: WET Clear all
Completed Phase 1Phase 2 Interventional Results available

Treating Depression With Transcranial Direct Current Stimulation (tDCS)

NCT00481988
View directory record Official record
Conditions
Depression
Interventions
transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Not applicable Interventional Results available

A Clinical Evaluation of a Honey Impregnated Dressing at Removing Necrotic Tissue From Chronic Wounds

NCT03412929
View directory record Official record
Conditions
Wound Heal, Necrotic Tissue Removal
Interventions
Honey Impregnated Dressing
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lake in the Hills, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

NCT01157065
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
AL-78898A, Ranibizumab
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 20, 2026, 2:29 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

NCT03276481
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Overnight Pant Study for Children With Nocturnal Enuresis

NCT05178641
View directory record Official record
Conditions
Nocturnal Enuresis
Interventions
Ninjamas Pyjama Pants, Participant's Overnight Current Standard of Care
Device · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
4 Years to 7 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 20, 2026, 2:29 PM EDT
Active, not recruiting Phase 3 Interventional

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064
View directory record Official record
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

NCT00100087
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Ocular Brachytherapy
Device
Lead sponsor
Theragenics Corporation
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 2:29 PM EDT
Recruiting Phase 4 Interventional

Pectoral Block in Breast Reduction for Pain Control

NCT07527039
View directory record Official record
Conditions
Macromastia (Symptomatic)
Interventions
Pectoral II Nerve Block, Post Operative Pain Relievers
Procedure · Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PAVES Benchmarking Pilot Study of Daily Disposable Contact Lenses

NCT04032457
View directory record Official record
Conditions
Refractive Errors
Interventions
Phase A - olifilcon B with Tangible Coatings, Phase B - etafilcon A with Tangible Coatings
Device
Lead sponsor
Vision Service Plan
Industry
Eligibility
18 Years to 42 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
6
States / cities
Atlanta, Georgia • Niles, Illinois • Carmel, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 20, 2026, 2:29 PM EDT
Not listed Phase 2 Interventional

Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration

NCT00996684
View directory record Official record
Conditions
Macular Degeneration
Interventions
Microplasmin, Placebo control
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 20, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional

A Biomechanical Evaluation of the Ossur Power Knee in Persons With Transfemoral Amputation

NCT06218238
View directory record Official record
Conditions
Transfemoral Amputation, Limb Loss, Limb Absence
Interventions
Powered prosthetic knee joint, Conventional microprocessor-controlled prosthetic knee joint
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed No phase listed Observational

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

NCT05082415
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950
View directory record Official record
Conditions
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions
LFG316, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers

NCT02844660
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
EpiCord, Standard of Care
Biological · Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Carlsbad, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
GW856553, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Hoffman Estates, Illinois • Park Ridge, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Not applicable Interventional

DAMP-Mediated Innate Immune Failure and Pneumonia After Trauma - the Harvard-Longwood (HALO) Campus Area Consortium

NCT03993002
View directory record Official record
Conditions
Respiratory Failure
Interventions
Normoxia with Normocarbia, Normoxia with Hypercarbia, Hyperoxia with Normocarbia, Hyperoxia with Hypercarbia
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD

NCT00793923
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
ranibizumab and dexamethasone, Ranibizumab
Drug
Lead sponsor
Subhransu K. Ray, M.D., Ph.D.
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

NCT03479372
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PAN-90806 Ophthalmic Suspension
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Golden, Colorado • Hagerstown, Maryland • Henderson, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Not applicable Interventional

An Efficient Treatment for Posttraumatic Injury for Firefighters

NCT05950035
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Insomnia, Nightmare
Interventions
Written Exposure Therapy (WET), Cognitive Behavioral Therapy for Insomnia (CBTi), Cognitive Behavioral Therapy for Nightmares (CBTn), Waitlist
Behavioral
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 20, 2026, 2:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Wells and Enteric Disease Transmission

NCT04826991
View directory record Official record
Conditions
Diarrhea, Gastrointestinal Infection, Respiratory Viral Infection, Waterborne Diseases
Interventions
Active UV Device, Inactive UV Device
Device
Lead sponsor
Temple University
Other
Eligibility
6 Months to 59 Months
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

NCT02282423
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies
Behavioral · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 20, 2026, 2:29 PM EDT
Enrolling by invitation Not applicable Interventional

Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails

NCT07490717
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD), Post-traumatic Stress Symptoms, Opioid Use Disorder (OUD), Stimulant Use Disorder, Stimulant Use & Co-occuring Opioid Use Disorders, Co-occurring Mental and Substance Use Disorders, Medications for Opioid Use Disorder
Interventions
Cognitive Processing Therapy (CPT), Written Exposure Therapy (WET)
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 20, 2026, 2:29 PM EDT